Thermo Fisher Scientific has agreed to acquire California-based point-of-care molecular diagnostic company Mesa Biotech in a deal worth up to $500 million. The consideration includes nearly $450 million in cash and an additional amount of up to $100 million, which will be subject to Mesa Biotech achieving certain milestones post-acquisition. The molecular diagnostic company has […]
Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, the shares of MyoKardia have ceased trading on the NASDAQ Global Select Market and the company is now a fully-owned subsidiary of Bristol Myers Squibb. As per the terms of […]
Continue reading …Adagio Medical, a California-based medical device company focused on developing treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), has raised $42.5 million in a Series E equity financing round. The company has also developed the intelligent Continuous Lesion Ablation System (iCLAS). Its Series E financing round included new investors ArrowMark Partners, Perceptive Advisors, and […]
Continue reading …Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]
Continue reading …Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate mavacamten. The US pharma giant is offering to acquire MyoKardia for $225.00 per share in an all-cash deal. Mavacamten is being developed for the treatment of a chronic heart disease […]
Continue reading …Illumina acquisition of GRAIL : US sequencing company Illumina has agreed to fully acquire California-based cancer screening company GRAIL in a cash and stock deal worth $8 billion. It was Illumina which had established GRAIL in 2016. Subsequently, it was separated as an independent company driven by Illumina’s NGS technology for developing data science and […]
Continue reading …Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to gain access to the latter’s FDA approved breast cancer drug Trodelvy (sacituzumab govitecan-hziy). Immunomedics, which has been offered $88 per share in cash by the US pharma giant, is focused […]
Continue reading …Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in the latter for about $2 billion. The deal is expected to help the Swiss conglomerate’s subsidiary Nestlé Health Science and Aimmune Therapeutics to create a global leader in the prevention […]
Continue reading …US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in the development of protein therapeutics, which are used in various commercial and development-stage biopharma drug candidates. As per the terms of the deal, Ligand Pharmaceuticals is offering to acquire the […]
Continue reading …Siemens Healthineers acquisition of Varian Medical Systems : Germany-based Siemens Healthineers has signed an all-cash deal worth around $16.4 billion to acquire US-based cancer care technologies developer Varian Medical Systems with an objective to strengthen its oncology portfolio and bolster its position in the healthcare sector. Based in California, Varian Medical Systems is among the […]
Continue reading …